• Profile
Close

Effect of clopidogrel and aspirin vs aspirin alone on migraine headaches after transcatheter atrial septal defect closure: One-year results of the CANOA randomized clinical trial

JAMA Sep 26, 2020

Wintzer-Wehekind J, Horlick E, Ibrahim R, et al. - In this prespecified analysis of a randomized clinical trial involving 171 patients (27 [15.8%] with new-onset migraine attacks), researchers evaluated the incidence of migraine attacks at 6- and 12-month follow-up after transcatheter atrial septal defect (ASD) closure. Study participants were randomized (1:1) to receive dual antiplatelet therapy (aspirin plus clopidogrel; n = 84) vs single antiplatelet therapy (aspirin plus placebo; n = 87) for 3 months following transcatheter ASD closure. In most patients, new-onset migraine attacks following ASD closure improved or resolved spontaneously within 6 to 12 months. After 3 months of clopidogrel cessation, no major rebound effect was observed. Such findings indicate a low rate of migraine events beyond 3 months after transcatheter ASD closure and support early discontinuation of clopidogrel therapy if administered.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay